Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › PMN

ProMIS Neurosciences

PMN Rare disease Lead: Phase 1 4 Biotech Distilled articles ↓ 21 filings & releases ↓ Cash $53.4M (Jun 30, 2026) ↓ 4 verdicts ↓ 2 timing quotes ↓
Neurology Protein

Market cap $37.3M 9.0M shares (10-Q, Aug 13, 2026) × $4.16 close Nov 6, 2026

Most recent annual filing: 2026-03-25

Catalyst timeline

3 trackedQuarter catalyst calendar →
  1. PMN310 FDA feedback2H 2026PMN310 FDA feedback, 2H 2026, notable
  2. PMN310 corporate update2H 2026PMN310 corporate update, 2H 2026, routine
  3. PMN310 topline1Q 2027PMN310 topline, 1Q 2027, thesis-defining

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (6 active programs)

Technology platforms

EpiSelect · University of British Columbia

Computational discovery platform using thermodynamics and statistical mechanics to model protein misfolding and identify disease-specific conformational epitopes on toxic misfolded proteins. Used to generate selective monoclonal antibodies, intrabodies, and therapeutic vaccines targeting neurodegenerative and misfolded protein diseases including Alzheimer's disease, ALS, Parkinson's disease, MSA, DLB, frontotemporal dementia, and schizophrenia.

Targets: amyloid beta oligomers, alpha-synuclein, TDP-43, tau, SOD1, RACK1, DISC1

EpiSelect

Computational platform to identify conformational epitopes uniquely exposed on toxic misfolded proteins, used to generate misfolding-specific antibodies or vaccine formulations targeting neurodegenerative diseases including Alzheimer's disease, ALS, FTD, Parkinson's disease, and multiple system atrophy.

Capital (as filed)

Cash
$53.4M cash and cash equivalents · Jun 30, 2026 (10-Q)
Short-term investments
$34K Jun 30, 2026
Operating cash flow
−$10.4M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$53.4M cash, runway through 2027 per the update of Oct 30, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (4)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (4 calls)

Every verdict Biotech Distilled has published on ProMIS Neurosciences, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-07-07 Watch ProMIS Neurosciences (PMN) — Scientific Deep Dive for PMN310 and Pipeline Products PMN310 has coherent science and an elite syndicate but zero human efficacy data, with a better-capitalized rival testing the same thesis first; wait for the late-2026 sabirnetug readout before committing.
  2. 2026-07-28 Watch UPDATE: ProMIS Neurosciences (PMN) - The Interim Gets a Date The blinded interim is low-information by design and the two gating events that actually change the risk/reward — the FDA Type B meeting and sabirnetug's topline — both arrive later; no reason to change stance.
  3. 2026-07-28 Speculative buy speculative UPDATE: ProMIS Neurosciences (PMN) - The Low-Information Print That Wasn't The 6-month interim delivered 0% ARIA-E across all genotypes including APOE4 homozygotes and two independent tau-pathway biomarkers moved favorably, converting the safety differentiation from hypothesis to observed human result and adding a mechanism signal earlier than expected.
  4. 2026-10-31 Watch UPDATE: ProMIS Neurosciences (PMN) - Someone Else's Exam, ProMIS's Grade Sabirnetug failed cleanly in a 542-patient Phase 2, breaking the fourth link in the oligomer thesis chain; the upgrade's biomarker logic now rests on an unproven link, and the market cap trading near cash is a cheap ticket on Q1 2027 rather than a thesis worth adding to.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (2 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (21)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jul 27, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

16 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)